Capital International Investors Increases Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital International Investors raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 27.8% during the first quarter, HoldingsChannel reports. The firm owned 7,837,074 shares of the company’s stock after buying an additional 1,702,624 shares during the quarter. Capital International Investors owned 0.09% of CRISPR Therapeutics worth $534,175,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of CRSP. Riggs Asset Managment Co. Inc. boosted its holdings in shares of CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares in the last quarter. Orion Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 44.0% in the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after buying an additional 220 shares in the last quarter. Wealthcare Advisory Partners LLC boosted its holdings in shares of CRISPR Therapeutics by 7.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock valued at $286,000 after buying an additional 300 shares in the last quarter. E Fund Management Co. Ltd. boosted its holdings in shares of CRISPR Therapeutics by 3.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,460 shares of the company’s stock valued at $592,000 after buying an additional 303 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 55.5% in the 1st quarter. Geneos Wealth Management Inc. now owns 871 shares of the company’s stock valued at $59,000 after buying an additional 311 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Piper Sandler reiterated an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Robert W. Baird raised their target price on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Barclays reduced their target price on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a research note on Thursday, May 9th. Finally, Citigroup reduced their target price on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, May 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average target price of $75.71.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Trading Up 0.6 %

Shares of CRSP traded up $0.35 during trading hours on Friday, reaching $57.92. The company had a trading volume of 866,898 shares, compared to its average volume of 1,603,022. The firm has a 50 day simple moving average of $57.16 and a 200-day simple moving average of $63.57. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10. The company has a market capitalization of $4.92 billion, a price-to-earnings ratio of -21.29 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $25.53 million. During the same period in the prior year, the business earned ($0.67) EPS. The company’s quarterly revenue was down 99.5% compared to the same quarter last year. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.